The evolving role of avotermin in scar prevention
Expert Review of Dermatology,

Nauta A et al. – Avotermin is a novel human recombinant TGF–beta 3 protein that has been studied both in vitro and in vivo for its antiscarring properties. This article evaluates a recently published Phase II clinical trial focused on the role of avotermin as a prophylactically administered, scar–reducing biologic agent for the treatment of human incisional wounds.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Dermatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Dermatology Articles

Indexed Journals in Dermatology: American Journal of Clinical Dermatology, Contact Dermatitis, Dermatologic Surgerymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close